

## HalioDx will develop new assays for QIAGEN in the frame of a multi-year and multi-project agreement

Marseille, France, June 27, 2016 – HalioDx SAS, an immuno-oncology diagnostic company, today announced the extension of its agreement with QIAGEN to incorporate new developments for cancer diagnostics.

Initially framed to cover a limited number of in-vitro-diagnostic (IVD) development projects conducted by HalioDx on behalf of QIAGEN, both companies have now agreed to extend this R&D service agreement for another four years to include additional cancer IVD development projects.

Partnering activities are conducted at HalioDx by a team of 60 highly qualified collaborators operating in the company facilities in Marseille, France, under the relevant quality system and a Design Control compliant process aligned with US and Europe regulatory requirements.

Stephane Debono, Executive Vice President Operations and Finances of HalioDx commented: *“The extension of our partnership with QIAGEN exemplifies our customer-centric vision and the talent and commitment of our teams in delivering on-time complex IVD projects in a highly regulated and competitive context. It is indeed a very positive signal for potential other partners such as pharma companies.”*

### About HalioDx SAS

#### The Immune Response to Cancer Diagnostics

By precisely measuring the immune reaction in and around the tumor, HalioDx tests allow the clinician to determine the degree of severity of the patient’s disease and predict the response to treatment, regardless of the cancer stage or the molecular class.

HalioDx designs and develops a unique range of immune scoring tests, whose first-in-class product is Immunoscore®. Considered a future diagnostic standard in Oncology, this biomarker has already demonstrated strong prognostic value in colorectal cancer.

HalioDx was founded in 2014 by the former management team of Ipsogen (leader in the molecular diagnosis of leukemia), and a pioneer in integrative immunology and oncology, Dr. Jérôme Galon.

HalioDx has an experienced team of 80 employees and compliant facilities to develop, manufacture, deliver and market in vitro diagnostic products and services in immuno-oncology.

For more information, please visit: [www.haliodx.com](http://www.haliodx.com)

HalioDx and Immunoscore are registered trademarks.

### Contacts

ATCG Press

Marie Puvieux (France), Mob: +33 (0)6 10 54 36 72

Jean-Mehdi Grangeon (ROW), Mob: +33 (0)6 62 22 00 24

[haliodx@atcg-partners.com](mailto:haliodx@atcg-partners.com)

[Twitter: twitter.com/haliodx](https://twitter.com/haliodx)